Daniel Alcalá-López

615 total citations
22 papers, 294 citations indexed

About

Daniel Alcalá-López is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Daniel Alcalá-López has authored 22 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Daniel Alcalá-López's work include Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (7 papers) and HER2/EGFR in Cancer Research (5 papers). Daniel Alcalá-López is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (7 papers) and HER2/EGFR in Cancer Research (5 papers). Daniel Alcalá-López collaborates with scholars based in Spain, Italy and France. Daniel Alcalá-López's co-authors include Danilo Bzdok, Kai Vogeley, Ferdinand Binkofski, Frank Van Overwalle, Elizabeth Jefferies, Angela R. Laird, Jonathan Smallwood, Simon B. Eickhoff, Peter T. Fox and Rogier B. Mars and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Daniel Alcalá-López

20 papers receiving 293 citations

Peers

Countries citing papers authored by Daniel Alcalá-López

Since Specialization

Citations

This map shows the geographic impact of Daniel Alcalá-López's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Alcalá-López with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Alcalá-López more than expected).

Fields of papers citing papers by Daniel Alcalá-López

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Alcalá-López. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Alcalá-López. The network helps show where Daniel Alcalá-López may publish in the future.

Co-authorship network of co-authors of Daniel Alcalá-López

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Alcalá-López. A scholar is included among the top collaborators of Daniel Alcalá-López based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Alcalá-López. Daniel Alcalá-López is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial 2025 ·The Lancet Oncology ·Jordi Remón, Paolo Bironzo, Nicolas Girard, L. Bigay-Gamé, Óscar Juan, Javier de Castro, Noemı́ Reguart, Laurent Greillier, Sophie Cousin, Éric Dansin, Margarita Majem, Reyes Bernabé, Joaquín Mosquera, (unknown), (unknown), Daniel Alcalá-López, (unknown), Luisella Righi, Silvia Novello, Benjamin Besse	1
2	Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study 2025 ·Journal of Thoracic Oncology ·Antonio Calles, Alejandro Navarro, (unknown), (unknown), Maria J. de Miguel, Rosa Álvarez, (unknown), Víctor Moreno, Pedro Rocha, Emiliano Calvo, (unknown), (unknown), Daniel Alcalá-López, Olga Boix, (unknown), José Rodríguez-Morató, Ramón Palmero, Ernest Nadal, Maria Jové, (unknown)	4
3	Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial 2025 ·Breast Cancer Research ·(unknown), (unknown), María Gión, Nuria Ribelles, (unknown), José Luis Alonso-Romero, Maria Martinez‐García, Santiago González-Santiago, Begoña Bermejo, Serafín Morales, Vicente Carañana, Laia Garrigós, (unknown), (unknown), (unknown), (unknown), Olga Boix, Daniel Alcalá-López, Antonio Llombart‐Cussac, Javier Cortés	0
4	Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study 2024 ·The Breast ·Alfonso Cortés, (unknown), (unknown), Vicente Carañana, Sònia Servitja, Ander Urruticoechea, (unknown), Antonia Márquez, (unknown), Daniel Alcalá-López, Leonardo Mina, Petra Gener, José Rodríguez-Morató, Gabriele Antonarelli, Antonio Llombart‐Cussac, José Manuel Pérez-García, (unknown)	1
5	Brain-wide representation of social knowledge 2024 ·Social Cognitive and Affective Neuroscience ·Daniel Alcalá-López, Ning Mei, (unknown), David Soto	0
6	LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria 2024 ·Annals of Oncology ·(unknown), (unknown), Serena Di Cosimo, Isabel Blancas, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Manuel Ruíz Borrego, Vega Iranzo, (unknown), Daniel Alcalá-López, Leonardo Mina, (unknown), (unknown)	3
7	Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC) 2024 ·Cancer Research ·Antonio Llombart‐Cussac, José Manuel Pérez-García, María Gión, Daniel Alcalá-López, (unknown), (unknown), Mario Mancino, (unknown), (unknown), (unknown), (unknown), Frauke Schimmöller, Matthew Wongchenko, Joseph Gligorov, Peter Schmid, Javier Cortés	1
8	Abstract PS11-05: Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study 2024 ·Cancer Research ·Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós, José Á. García-Sáenz, (unknown), (unknown), Salvador Blanch, Manuel Ruíz Borrego, (unknown), María Fernández, Vega Iranzo, María Gión, (unknown), Daniel Alcalá-López, Jhudit Pérez‐Escuredo, Miguel Sampayo-Cordero, Antonio Llombart‐Cussac, Sofía Braga, Javier Cortés	4
9	Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study 2024 ·European Urology Oncology ·Xavier García del Muro, D. Páez López-Bravo, (unknown), Pablo Maroto, Patrizia Giannatempo, Daniel Castellano, Miguel Ángel Climent, Begoña P. Valderrama, Alfonso Gómez de Liaño, (unknown), Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo-Cordero, Andrea Necchi	6
10	LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma 2024 ·Annals of Oncology ·J. Remon Masip, Paolo Bironzo, N. Girard, (unknown), Óscar Juan, Javier de Castro, (unknown), Laurent Greillier, Sophie Cousin, Éric Dansin, (unknown), Reyes Bernabé, Joaquín Mosquera, (unknown), (unknown), Daniel Alcalá-López, (unknown), (unknown), (unknown), B. Besse	3
11	Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial 2024 ·ESMO Open ·Marta Vaz Batista, José Manuel Pérez-García, (unknown), Laia Garrigós, María Fernández, María Gión, (unknown), Cristina Saavedra, (unknown), (unknown), Sònia Servitja, Manuel Ruíz‐Borrego, Juan de la Haba-Rodríguez, (unknown), Jhudit Pérez‐Escuredo, Daniel Alcalá-López, Miguel Sampayo-Cordero, Sofía Braga, Javier Cortés, (unknown)	11
12	Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial. 2024 ·Journal of Clinical Oncology ·(unknown), José Manuel Pérez García, María Gión, Nuria Ribelles, (unknown), (unknown), Maria Martinez‐García, Santiago González Santiago, Begoña Bermejo, Serafín Morales, Vicente Carañana, Laia Garrigós, (unknown), Olga Boix, Daniel Alcalá-López, Javier Cortés, Antonio Llombart‐Cussac	3
13	The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis 2024 ·Med ·Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós, José Á. García-Sáenz, (unknown), (unknown), Salvador Blanch, Manuel Ruíz‐Borrego, (unknown), María Fernández, Vega Iranzo, María Gión, (unknown), Daniel Alcalá-López, Jhudit Pérez‐Escuredo, Miguel Sampayo-Cordero, Antonio Llombart‐Cussac, Sofía Braga, Javier Cortés	13
14	260P LUZERN: Phase II trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer 2024 ·ESMO Open ·(unknown), (unknown), (unknown), José Á. García-Sáenz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Daniel Alcalá-López, (unknown), (unknown), (unknown)	1
15	Phase II study of the efficacy of retifanlimab (Rf) (INCMGA00012) in penile squamous cell carcinoma (PSqCC): ORPHEUS final analysis. 2023 ·Journal of Clinical Oncology ·Xavier García del Muro, (unknown), (unknown), Patrizia Giannatempo, Daniel Castellano, Andrea Necchi, Miguel Ángel Climent, Begoña P. Valderrama, Alfonso Gómez de Liaño, David Molina, Leonardo Mina, Daniel Alcalá-López, (unknown), David Páez	3
16	A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer 2023 ·Frontiers in Oncology ·Miguel Sampayo-Cordero, (unknown), Andrea Malfettone, (unknown), María Gión, Elena Abad, Daniel Alcalá-López, Jhudit Pérez‐Escuredo, José Manuel Pérez-García, Antonio Llombart‐Cussac, Javier Cortés	3
17	Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. 2023 ·Journal of Clinical Oncology ·Antonio Llombart‐Cussac, Catherine Harper‐Wynne, Antonia Perelló, Audrey Hennequin, (unknown), Marco Colleoni, Vicente Carañana, Vanesa Quiroga, Jacques Médioni, Vega Iranzo, Duncan Wheatley, Sonia Del Barco, Antonio Antón, Erion Dobi, Manuel Ruíz‐Borrego, Daniel Alcalá-López, Jhudit Pérez‐Escuredo, Miguel Sampayo-Cordero, José Manuel Pérez-García, Javier Cortés	42
18	3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). 2023 ·Journal of Clinical Oncology ·Javier Cortés, José Manuel Pérez-García, Manuel Ruíz-Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escrivá-de-Romaní, Lourdes Calvo, Nuria Ribelles, (unknown), (unknown), Marco Colleoni, Géraldine Gebhart, Aleix Prat, Khaldoun Kerrou, Peter Schmid, Serena Di Cosimo, Crina Popa, Daniel Alcalá-López, Miguel Sampayo-Cordero, Antonio Llombart‐Cussac	14
19	Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study 2022 ·Cancers ·(unknown), Sonia Del Barco Berrón, (unknown), (unknown), (unknown), Alfonso Cortés, Pedro Sánchez‐Rovira, Alejandro Martínez‐Bueno, Xavier González, (unknown), Petra Gener, Leonardo Mina, Daniel Alcalá-López, (unknown), Javier Cortés, José Manuel Pérez-García, Antonio Llombart‐Cussac, (unknown)	2
20	Building blocks of social cognition: Mirror, mentalize, share? 2018 ·Cortex ·Daniel Alcalá-López, Kai Vogeley, Ferdinand Binkofski, Danilo Bzdok	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact